GU CONNECT has summarised the highlights of the recent ASCO GU 2019 meeting for you.


Prostate Cancer by Dr. Neal Shore, Carolina Urologic Research Center, South Carolina, USA

 

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Dr Neal D. Shore has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, Astellas, Amgen, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Lantheus, Lilly, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Photocure, Propella, PreView, Sanofi Genzyme, Sema4, Speciality Networks, Sesen Bio, Telix, Tempus, Tolmar and Urogen, Vaxiion.

Programme summary
Watch the video now
Other episodes of this series
Update from ASCO GU 2019

Update from ASCO GU 2019

Episode 1 Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

ipcv Interactive Patient Case Video (IPCV)

Episode

1

of 1

episode
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
micro-learning Micro learning - Video, slides and more

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Oct 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

2

of 2

episode
Oncology 
Clinical implementation of testing and PARPis in combination with NHAs

Episode 2: Clinical implementation of testing and PARP inhibitors in combination with NHAs

Experts
Dr Andrew J. Armstrong
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

1

of 2

episode
Oncology 
Clinical implementation of testing and PARPi as monotherapy

Episode 1: Clinical implementation of testing and PARPi monotherapy

Experts
Dr Neal Shore
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Video podcast
Oncology 
Which mCSPC patients benefit from early treatment intensification?

A podcast from GU oncology experts

Experts
Assoc. Prof. Shilpa Gupta, Dr Fabio Schutz
  • download Downloadable
    Resources
  • clock 22 MIN
  • calendar Mar 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer
conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education